Vol.

No.

January 25, 2019Jan 25, 2019

Free

DOWNLOAD THE PDF

Why austerity measures amid Congressional generosity? Sharpless explains the counterintuitive Sharpless explains the counterintuitive

Cover Story

Conversation with The Cancer Letter Free

Why austerity measures amid Congressional generosity? Sharpless explains the counterintuitive

Sharpless explains the counterintuitive

By Paul Goldberg

In recent years, NCI spending on extramural research has been following the same trajectory as Congressional appropriations for the institute: up, up, up.

Free

FDA approves 19 new cancer drugs and biologics in 2018—and don't forget two new endpoints and “real-time” review

By Claire Dietz and Matthew Bin Han Ong

Conversation with The Cancer Letter Free

Brawley aims to create a “huge collaboration” in research on disparities

By Paul Goldberg

In Brief

Rosanna Morris named chief operating officer at MD Anderson

Health groups call for speedy end of shutdown

Kyn Therapeutics partners with Celgene to develop immuno-oncology therapies

Funding Opportunities

Colorectal Cancer Alliance announces funding recipients for colon and rectal cancer research needs

Funding opportunities for FY19–DOD Breast Cancer Research Program

Clinical Roundup

Finasteride found to be safe, effective prevention for prostate cancer

Remote participation enables patients with ALK-positive lung cancer to enroll in study of treatment resistance

Servier & Taiho present Lonsurf data at ASCO 2019 GI Symposium

New test for esophageal cancer could save millions of lives

AbbVie's Imbruvica fails late-stage pancreatic cancer study

Drugs & Targets

European Commission authorizes Rubraca tablets in ovarian cancer

Bristol-Myers Squibb withdraws U.S. application for Opdivo + Yervoy in first-line lung cancer

FDA finalizes policy on labeling for accelerated approval drugs

FDA grants Illumina's TruSight Assay Breakthrough Device designation

Amgen's Blincyto approved in Europe for leukemia

Genmab initiates of FDA submission for expansion of daratumumab in multiple myeloma

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues